{
  "docId": "019de514-833c-7520-a4a9-200b68fbb681",
  "docSlug": "d869e39fe11534a9d64784c9e4f475f2",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 47 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 47,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de514-833c-7520-a4a9-200b68fbb681/29",
  "deckHref": "/decks/019de514-833c-7520-a4a9-200b68fbb681",
  "deckJsonHref": "/decks/019de514-833c-7520-a4a9-200b68fbb681.json",
  "deckAnchorHref": "/decks/019de514-833c-7520-a4a9-200b68fbb681#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.607,
        "x": 0.16,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. See slide 1 for further information on forward-looking statements.\n2. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of NOV03 in the United States and Canada.\n3. Exclusive licensing agreement with STADA Arneimittel AG and Xbrane Biopharma AB for U.S. and Canada.\n4. Exclusive licensing agreement with Eyenovia, Inc. for U.S. and Canada.\n5. Abbreviated biologics license application.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ddd2b06-765f-4356-b1e9-f33bddc2d97d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.87,
        "x": 0.046,
        "y": 0.253
      },
      "kind": "table",
      "text": "Ophthalmic Pharmaceuticals\nProduct\nStatus\nUpcoming Milestone\nVYZULTA® geo-expansion\nLaunched in 15 countries\nExpected to launch in ~10 additional countries in 2023+\nNOV03² (dry eye disease associated with meibomian gland dysfunction)\nFDA accepted NDA in September 2022\nPDUFA date June 28, 2023\nBiosimilar candidate for Lucentis (ranibizumab)³\nXbrane withdrew aBLA⁵ after receiving feedback from FDA that supplemental information would be required\nResubmission target date expected by end 2022\nMicrodose formulation of atropine ophthalmic solution (reduction of pediatric myopia progression in children ages 3-12)⁴\nClinical trial enrollment completion is delayed from 4Q22 to 1H23 due to clinical trial material availability",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "445540ba-dd9e-4e6d-9aa3-7dbd1b8ba4b7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "6ae7a389-de75-4c6b-994e-03f4fe777cad",
      "evidence": "table/data: Ophthalmic Pharmaceuticals",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}